BRPI0416906A - proteinúria tubular como um indicador para risco cardiovascular elevado - Google Patents

proteinúria tubular como um indicador para risco cardiovascular elevado

Info

Publication number
BRPI0416906A
BRPI0416906A BRPI0416906-9A BRPI0416906A BRPI0416906A BR PI0416906 A BRPI0416906 A BR PI0416906A BR PI0416906 A BRPI0416906 A BR PI0416906A BR PI0416906 A BRPI0416906 A BR PI0416906A
Authority
BR
Brazil
Prior art keywords
indicator
cardiovascular risk
tubular
tubular proteinuria
elevated cardiovascular
Prior art date
Application number
BRPI0416906-9A
Other languages
English (en)
Inventor
Joachim Schrader
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0416906A publication Critical patent/BRPI0416906A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PROTEINúRIA TUBULAR COMO UM INDICADOR PARA RISCO CARDIOVASCULAR ELEVADO". A presente invenção refere-se ao uso de um inibidor ACE ou de um antagonista receptor de angiotensina, para a preparação de uma composição farmacêutica para reduzir proteinúria tubular e/ou <244>~ 1~-microglobulina em um indivíduo humano não-diabético, a fim de reduzir o risco de um evento cardiovascular.
BRPI0416906-9A 2003-11-26 2004-11-26 proteinúria tubular como um indicador para risco cardiovascular elevado BRPI0416906A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027312 2003-11-26
PCT/EP2004/013511 WO2005051379A1 (en) 2003-11-26 2004-11-26 Tubular proteinuria as an indicator for elevated cardiovascular risk

Publications (1)

Publication Number Publication Date
BRPI0416906A true BRPI0416906A (pt) 2007-01-16

Family

ID=34626378

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416906-9A BRPI0416906A (pt) 2003-11-26 2004-11-26 proteinúria tubular como um indicador para risco cardiovascular elevado

Country Status (10)

Country Link
US (2) US20060264488A1 (pt)
EP (1) EP1689386A1 (pt)
JP (1) JP2007513884A (pt)
KR (1) KR20060110306A (pt)
CN (1) CN1882331A (pt)
AU (1) AU2004292775A1 (pt)
BR (1) BRPI0416906A (pt)
CA (1) CA2547124A1 (pt)
IL (1) IL175792A0 (pt)
WO (1) WO2005051379A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008214837B2 (en) * 2007-02-12 2013-01-10 A1M Pharma Ab Diagnosis and treatment of preeclampsia
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
CA2881321A1 (en) * 2012-09-05 2014-03-13 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
CN103903553A (zh) * 2014-03-14 2014-07-02 四川虹欧显示器件有限公司 一种解决高Xe含量下画面切换后低放电的方法

Also Published As

Publication number Publication date
JP2007513884A (ja) 2007-05-31
US20060264488A1 (en) 2006-11-23
WO2005051379A1 (en) 2005-06-09
CN1882331A (zh) 2006-12-20
AU2004292775A1 (en) 2005-06-09
US20070191446A1 (en) 2007-08-16
IL175792A0 (en) 2008-04-13
KR20060110306A (ko) 2006-10-24
CA2547124A1 (en) 2005-06-09
EP1689386A1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
WO2007038138A3 (en) Amido compounds and their use as pharmaceuticals
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
WO2006020598A3 (en) Amido compounds and their use as pharmaceuticals
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2006012227A3 (en) Amido compounds and their use as pharmaceuticals
CL2007002017A1 (es) Compuestos derivados de [4,5&#39;]-bipirimidinil-6,4&#39;-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
SG161261A1 (en) Lactam compounds and their use as pharmaceuticals
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0811180A2 (pt) Uso de probióticos ou uma mistura dos mesmos para a preparação de composição farmacêutica utilizável em um ambiente pré e/ou pós-cirúrgico.
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
SG152257A1 (en) Topical preparation containing ambroxol
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
HRP20050713A2 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
MX2010000997A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
BRPI0410739A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa)
CL2008000683A1 (es) Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de la enzima de conversion de angiotensina (ace); formulacion de dosis unitaria; y uso en el tratamiento de la diabetes.
MY177591A (en) Nk1 receptor antagonist composition
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BRPI0416906A (pt) proteinúria tubular como um indicador para risco cardiovascular elevado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.